Board of Directors
Our Board has been a source of stability and experience that has helped guide and direct Vertex’s growth from a small research startup to a global S&P 500 company that launched three breakthrough medicines in six years.
Over time, the Board has evolved to meet Vertex’s needs and help the company achieve our future goals. Moving forward, our Board will continue to play a critical role in helping Vertex successfully transition into a sustainably profitable company that produces more transformative medicines for people around the world living with serious diseases.
Jeffrey Leiden, M.D., Ph.D.
Dr. Leiden is the Executive Chairman of Vertex Pharmaceuticals. He has served as a member of Vertex's board of directors since 2009. Dr. Leiden has more than 20 years of scientific, commercial and financial experience in the pharmaceutical and biotechnology industries as well as clinical and scientific experience in academia as a practicing cardiologist and molecular biologist. Read more
Reshma Kewalramani, M.D., FASN
President and CEO
Reshma Kewalramani, M.D., FASN, is the President and Chief Executive Officer at Vertex. Dr. Kewalramani has dedicated her career to improving the lives of patients, including the last 15+ years through the development of new medicines. She joined Vertex in 2017 and was previously the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. Read more
Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Bhatia joined the Vertex Board in June 2015. She currently serves as the John J. and Dorothy Wilson Professor of Health Sciences at the Massachusetts Institute of Technology’s (MIT) Institute for Medical Engineering and Science and Electrical Engineering and ComputerScience (EECS), where she has worked since 2005.
Mr. Carney joined the Vertex Board in February 2019. He is a prominent technology executive with experience leading innovative, high-growth organizations. He currently serves as the Chairman and Chief Executive Officer of ChaSerg Technology Acquisition Corp., a technology acquisition company.
Alan Garber, M.D., Ph.D.
Dr. Garber joined the Vertex Board in June 2017. He is currently the Provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, the Professor of Public Policy in the Harvard Kennedy School of Government, and a Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health.
Terrence C. Kearney
Mr. Kearney joined the Vertex Board in May 2011 and has more than three decades of global healthcare experience at major pharmaceutical and life sciences companies.
Mr. Lee joined the Vertex Board in September 2012. He was most recently the Vice President and General Manager of IBM’s Enterprise Marketing Management Group, where he directed a team of nearly 2,000 IBM employees and was a key architect in IBM’s global initiative to serve the needs of Chief Marketing Officers.
Ms. McGlynn joined the Vertex Board in May 2011. She served as the President and Chief Executive Officer of the International AIDS Vaccine Initiative (IAVI), a global not-for-profit organization whose mission is to ensure the development of safe, effective and accessible HIV vaccines for use throughout the world, from 2011 through 2015.
Bruce I. Sachs
Mr. Sachs joined the Vertex Board in 1998 and is the Board's co-lead independent director. He brings to Vertex many years of experience working with companies in high-growth business environments as an executive and as a general partner of Charles River Ventures, since 1999.
William Young, Ph.D.
Dr. Young joined the Vertex Board in May 2014 and has extensive experience in leadership roles within major life sciences and pharmaceutical companies.
The following table provides the committee membership for our board of directors.